对比增强CT影像基因组学在回顾性非小细胞肺癌队列中的研究:模型构建、对已发表模型的验证尝试及临床背景的相关性
回顾性纳入157例治疗前行胸部对比增强CT且在本机构完成肿瘤基因组测序的非小细胞肺癌患者,构建两个影像基因组学预测模型(M1、M2)并在本队列中测试一个已发表的EGFR影像组学模型。M1与M2联合临床变量后对EGFR的预测中位AUC分别达0.80与0.81;外部EGFR模型影像组学单独AUC为0.69,联合临床变量为0.86。作者认为对比增强CT影像组学可产生稳健的预测模型,临床变量对模型性能影响显著。
要点
- 联合临床变量可提升影像组学模型对EGFR突变的预测性能。
- M1与M2模型对TP53、KRAS的预测中位AUC多在0.53至0.64之间。
- 外部已发表EGFR模型在本队列影像组学单独AUC为0.69,联合临床变量为0.86。
核心结论
- 本研究为TP53、KRAS和EGFR突变的检测提供了稳健的预测影像组学模型评估,并与已发表模型进行了性能比较,观察到临床变量可对模型性能产生显著影响。
研究设计与样本
- 回顾性研究,纳入157例治疗前行胸部对比增强CT且在本机构完成肿瘤基因组测序的非小细胞肺癌患者,数据来自影像检查、电子病历及基于网络的数据库检索(cBioPortal.ca),构建两个预测模型(M1与M2)并另从文献提取第三个模型在本队列中测试。
诊断标准与关键数值
- M1影像组学单独模型对TP53、KRAS、EGFR的中位AUC分别为0.61、0.53、0.64,M1影像组学联合临床对三者分别为0.61、0.61、0.80。
- M2影像组学单独模型对TP53、KRAS、EGFR的中位AUC分别为0.63、0.60、0.65,M2影像组学联合临床对三者分别为0.64、0.62、0.81。
- 外部EGFR影像组学模型在本队列影像组学单独AUC为0.69,影像组学联合临床AUC为0.86。
临床应用与阅片要点
- 原文结论指出,对于无法接受活检的患者,识别肿瘤突变对其结局至关重要。
- 原文要点指出,肿瘤基因组图谱对治疗选择至关重要。
- 原文要点指出,对比增强CT影像组学可产生与已发表模型相当的稳健预测模型。
- 原文要点指出,预测模型应考虑或纳入临床变量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVE: To develop a radiogenomic predictive model for non-small cell lung cancer (NSCLC) patients studied through contrast enhanced chest computed tomography (CE-CT) targeting the most frequent gene alterations. M&M: A retrospective study of patients with NSCLC imaged with CE-CT before treatment and had their tumor genomics sequenced at our institution was performed. Data was gathered from their imaging studies, their electronic medical records and a web-based database search (cBioPortal.ca). All of the patient data was tabulated for analysis. Two predictive models (M1 & M2) were created using different approaches and a third model was extracted from the literature to also be tested in our population.
RESULTS: Out of 157 patients, eighty were male (51%) and 124 (79%) had a history of smoking. The three most prevalent genes were KRAS, TP53 and EGFR. The M1 radiomics-only model median AUC were 0.61 (TP53), 0.53 (KRAS) and 0.64 (EGFR) and for M1 radiomics + clinical were 0.61 (TP53), 0.61 (KRAS) and 0.80 (EGFR). The M2 radiomics-only model median AUC were 0.63 (TP53), 0.60 (KRAS) and 0.65 (EGFR) and for M2 radiomics + clinical were 0.64 (TP53), 0.62 (KRAS) and 0.81 (EGFR). The external EGFR radiomic model showed an AUC of 0.69 and 0.86 for the radiomics-only and combined radiomics + clinical respectively.
CONCLUSION: Our study was able to provide robust predictive radiomics model evaluation for the detection of TP53, KRAS and EGFR. We also compared our performance with an already published model and observed how impactful clinical variables can be on models' performance.
CLINICAL RELEVANCE STATEMENT: Identifying tumor mutations in patients that can't undergo biopsy is critical for their outcomes.
KEYPOINTS: • Tumor genomic profiling is critical for treatment selection • CE-CT radiomics produce robust predictive models comparable to those already published • Clinical variables should be considered/included in predictive models.
引用
- Kohan A, Hinzpeter R, Kulanthaivelu R, et al. Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context. Acad Radiol. 2024. PMID: 38383258. doi:10.1016/j.acra.2024.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。